TARSUS PHARMACEUTICALS, INC. (TARS)

90.78USD +9.10% (+7.58)

Over 1M: +40.1%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

70 80 90
7 Aug 12 Aug 17 Aug 20 Aug 25 Aug 28 Aug 2 Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '23 — Operating Income: -40.9M Q4 '23 — Operating Income: -44.5M Q1 '24 — Operating Income: -37.7M Q2 '24 — Operating Income: -33.3M Q3 '24 — Operating Income: -25.2M Q4 '24 — Operating Income: -24.4M Q1 '25 — Operating Income: -26.3M Q2 '25 — Operating Income: -22.2M Q3 '25 — Operating Income: -14.5M Q4 '25 — Operating Income: -8M Q1 '26 — Operating Income: -6.1M Q2 '26 — Operating Income: -19.9M -36M -27M -18M -9M 0
Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Gross Profit Operating Income

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

2.5
OE margin 0.69%
Oper. margin -8.0%
Accruals -19.7%
Gross margin 96.5%
FCF margin 9.2%
OCF margin 12.2%
ROA -7.6%
ROCE -11.1%
ROE -13.4%
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

4.5
EV/Sales 5.9×
EV/OE 860.8×
P/C 8.9×
FCF yield 1.4%
P/B 11.5×
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.8
ND/EBITDA 0.1
Cash / Debt 6.2×
Debt payback 0.0 yr
Quick ratio 3.2×
Debt / Eq 0.21×
F-score 4.5 pts
Cash runway —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

9.7
Sales/sh Y/Y +84.6%
Sales CAGR 4Y +67.7%
Sales Q/Q +69.4%
Shares change +11.1%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.